Tag Archives: BioMerieux

Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More

Finding and enrolling patients for clinical trials is always challenging. The coronavirus pandemic has made it nearly impossible. Fallout from the spread of COVID-19 infections led several companies to declare this week that they would stop enrolling patients in clinical trials or postpone studies that have not yet started. Eli Lilly (NYSE: LLY) said that […]

Bought By Utah Rival Tute, Former Genomics High Flyer Knome Bows Out

After eight years, more than $20 million raised, and a handful of different business plans, genomics firm Knome has been acquired by tiny Tute Genomics of Provo, UT, for what appears to be a substantial loss. The parties are not disclosing the purchase price, but it’s likely to be a fraction of what Knome investors […]

Posted in Boston, Boston blog main, National blog main, National top stories | Tagged Acquisition, Amgen, BioMerieux, Biotech, Buyout, Canepa Healthcare, Central United States Earthquake Consortium, David Mittelman, deCODE Genetics, Electronic Health Records, Foundation Medicine, Genetics, Genomics, George Church, Harvard, Johns Hopkins University, Knome, lab in a box, Life Science, Life Sciences, M&A, Martin Tolar, Merger, ModeRNA Therapeutics, NextCode Health, Ozzy Osbourne, Paul enever, Provo, Purchase, Reid Robison, Roche, Stephane Bancel, Tute Genomics, WuXi PharmaTech | Comments Off

T2 Biosystems Sputters Through IPO Queue, Raises $57M

If the question was how a diagnostics company would fare in a sputtering IPO market, the answer for T2 Biosystems was: not too well. The Lexington, MA-based company priced well below its projected range, raising about $57.2 million before paying its underwriters. T2 aimed to raise as much as $68 million by selling 4 million […]

Posted in Boston, Boston blog main, National blog main | Tagged Aisling Capital, Auris Medical, Avalanche Biotechnologies, Becton Dickinson, BioMerieux, Bob Langer, Diagnostics, Flagship Ventures, Flybridge Capital Partners, Foundation Medicine, Goldman Sachs, hemostasis, IPO, Janney Montgomery Scott, Lee Josephson, Leerink Partners, Life Sciences, Michael Cima, Microlin Bio, MIT, morgan stanley, Physic Venture, Polaris Partners, Ralph Weissleder, Sage Therapeutics, Sepsis, Tyler Jacks, VC | 1 Comment

9 Takeaways from Boston’s Life Science Disruptors

Building a biotech is (really) hard. But if you’re doing to do it, be yourself. Don’t take yourself too seriously. Wear sneakers if you feel like it. Near-death experiences happen to everyone along the way—embrace them and learn. And if your initial hunch is that the company’s founding idea is insane, it’s probably worth pursuing. […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories | Tagged AstraZeneca, BDO, BioMerieux, BlueBird Bio, Cubist Pharmaceuticals, Darren Higgins, Genocea Biosciences, Genzyme, Harvard University, Health Advances, Kauffman Foundation, KeithSpiroPhoto, Kendall Press, Kevin Bitterman, Life Sciences, Mintz Levin Cohn Ferris Glovsky and Popeo, ModeRNA Therapeutics, Neil Exter, Nick Leschly, Noubar Afeyan, Novartis, Pascal Soriot, startups, Stephane Bancel, VC | Comments Off

NeuroPhage Pharmaceuticals Secures $6,400,000 New Funding Round

Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=b5118b94-342d-4512-bb0a-51b945378589&Preview=1 Date 5/6/2013 Company Name NeuroPhage Pharmaceuticals Mailing Address 222 3rd St. Cambridge, MA 02142 Company Description NeuroPhage is developing a breakthrough protein dissaggregation platform for treatment of neurodegenerative diseases. Our lead Alzheimer’s disease (AD) drug candidate, NPT001, safely and effectively dissaggregates existing Aß plaque in preclinical animal models, which is unique […]

Posted in Boston, Boston VentureDeal VC | Tagged BioMerieux, BostonVC, NeuroPhage Pharmaceuticals, Shire Strategic Investment Group, Undisclosed | Comments Off

Moderna, $40M in Tow, Hopes to Reinvent Biotech with “Make Your Own Drug”

Noubar Afeyan, Bob Langer, Tim Springer, and a host of other Boston biotech luminaries have been sitting on a big secret. Today we’re going to out them. Moderna Therapeutics, a stealthy startup in Cambridge, MA, is the subject of their considerable brainpower and experiments. The company is finally emerging from stealth, having raised $40 million […]

Posted in Boston, Boston blog main, National blog main, National top stories | Tagged Big Pharma, BioMerieux, Biotech, Bob Langer, Derrick Rossi, Drugs, Eli Lilly, Flagship Ventures, Genentech, Harvard Medical School, Ken Chien, LeukoSite, Life Sciences, Massachusette General Hospital, messenger RNA, Millennium Pharmaceuticals, MIT, ModeRNA Therapeutics, mRNA, Noubar Afeyan, Shinya Yamanaka, startups, Stem Cells, Stephane Bancel, Tim Springer, VC, Venture Capital | 16 Comments

Celgene Pumps Up Acceleron, On-Q-ity CEO Goes to Roche Unit, MSMB Eyes Amag, & More Boston-Area Life Sciences News

We caught some personnel updates and other news from public and private New England companies developing drugs, medical devices, and diagnostics technology. —Woburn, MA-based Pathogenetix, the diagnostics and biodefense company formerly known as U.S. Genomics, raised $4 million of a targeted $9.5 million equity financing. —Beacon Endoscopic, a Newton, MA-based startup that’s developed a fine […]

Posted in Boston, Boston blog main, National blog main | Tagged Allos Therapeutics, AMAG Pharmaceuticals, Beacon Endoscopic, BG Medicine, BioMerieux, cancer, deals, Diagnostics, Financing, funding, Genomics, George Church, Knome, Life Sciences, Mara Aspinall, medical devices, ModeRNA Therapeutics, MSMB Capital Management, On-Q-ity, Partnership, Pathogenetix, Private Equity, Roche, Roundup, Stephane Bancel, U.S. Genomics, Ventana Medical Systems | Comments Off

Stéphane Bancel, Former bioMérieux CEO, Talks Future of Startups, Diagnostics, Pharma

Amid all the comings and goings and CEOs changing jobs in the past week—see Rick Reidy of Progress Software (NASDAQ: PRGS), Mara Aspinall of On-Q-ity, and others—one person flew under the radar in Boston. He is Stéphane Bancel, and until last month he was the CEO of bioMérieux, the microbiology and diagnostics firm based in […]

Posted in Boston, Boston blog main, National blog main | Tagged Analysis, Bacteria, BG Medicine, BioMerieux, Biotech, cancer, Diagnostics, Eli Lilly, Flagship Ventures, Food Safety, France, Genomics, George Church, Global Health, Harvard University, healthcare, hospitals, Knome, Life Sciences, ModeRNA, molecular diagnostics, people, Personalized Medicine, Pfizer, pharma, Sequencing, startups, Stephane Bancel, trends | 44 Comments

NeuroPhage Pharmaceuticals Garners $12,400,000 Series B Financing

Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=ad05020f-0c6a-45f6-9111-8c4c2cb69ca4&Preview=1 Date 3/1/2011 Company Name NeuroPhage Pharmaceuticals Mailing Address 222 3rd St. Cambridge, MA 02142 Company Description NeuroPhage is developing a breakthrough protein dissaggregation platform for treatment of neurodegenerative diseases. Our lead Alzheimer’s disease (AD) drug candidate, NPT001, safely and effectively dissaggregates existing Aß plaque in preclinical animal models, which is unique […]

Posted in Boston, Boston VentureDeal VC | Tagged BioMerieux, BostonVC, NeuroPhage Pharmaceuticals, Undisclosed | Comments Off

Warner Bros. Acquires Turbine, Athenahealth Taps IBM, Alkermes Reveals Diabetes Drug Royalty, & More Boston-Area Deals News

News of financings, partnerships, royalties, and acquisitions among New England’s video game, transportation, biotech, and energy companies have kept us buzzing in the last week. —Westwood, MA-based online games maker Turbine was purchased by the Home Entertainment Group of Warner Bros. Interactive Entertainment, a unit of Time Warner (NYSE: TWX). Turbine produces the massively multiplayer […]

Posted in Boston, Boston blog main, National blog main | Tagged Acquisition, Alkermes, Alnylam Pharmaceuticals, Amylin Pharmaceuticals, Athenahealth, BioMerieux, Biotech, Bydureon, CB Insights, Charles River Laboratories International, cleantech, deals, Devices, Diagnostics, Dow Jones VentureSource, Drugs, electronic medical records, electronics, Eli Lilly, energy, Entrepreneurship, ethanol, Exenatide, Financing, funding, Healthtech, Joule Biotechnologies, Joule Unlimited, Knome, Life Sciences, Mascoma, Matrix Partners, Michigan Economic Development Corporation, MoneyTree Report, motion sensors, Novartis, Partnerships, pharma, Pilot House Ventures, Pluromed, Qualtre, Roundup, Software, startups, Streetcar, Time Warner, turbine, VC, Venture Capital, Warner Bros., WuXi PharmaTech, ZipCar | Comments Off← Older posts

Tag Archives: BioMerieux

Archives

Meta